Role of human herpesvirus 8 interleukin-6-activated gp130 signal transducer in primary effusion lymphoma cell growth and viability

Journal of Virology

Volumn 87, Issue 19, 2013, Pages 10816-10827

  Cousins, Emily ^a   Nicholas, John ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; SHORT HAIRPIN RNA; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1 VARIANT PROTEIN 2;

ARTICLE; CANCER CELL CULTURE; CELL COMPARTMENTALIZATION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; LYMPHOMA CELL; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; VIRUS IMMUNITY;

HUMAN HERPESVIRUS 8;

EID: 84886062795     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02047-13     Document Type: Article

References (41)

1. Ensoli B, Sturzl M, Monini P. 2001. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. Adv. Cancer Res. 81:161-200.
2. Schulz TF. 2006. The pleiotropic effects of Kaposi's sarcoma herpesvirus. J. Pathol. 208:187-198.
3. Uldrick TS, Polizzotto MN, Yarchoan R. 2012. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Curr. Opin. Oncol. 24:495-505.
4. Nicholas J. 2007. Human herpesvirus 8-encoded proteins with potential roles in virus-associated neoplasia. Front. Biosci. 12:265-281.
5. Sakakibara S, Tosato G. 2011. Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J. Interferon Cytokine Res. 31:791-801.
6. Jones KD, Aoki Y, Chang Y, Moore PS, Yarchoan R, Tosato G. 1999. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood 94:2871-2879.
7. Chandriani S, Ganem D. 2010. Array-based transcript profiling and limiting-dilution reverse transcription-PCR analysis identify additional latent genes in Kaposi's sarcoma-associated herpesvirus. J. Virol. 84:5565-5573.
8. Chen D, Sandford G, Nicholas J. 2009. Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6. J. Virol. 83: 722-733.
9. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. 1997. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J. Biol. Chem. 272:19625-19631.
10. Chen D, Nicholas J. 2006. Structural requirements for gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence for gp80 stabilization of gp130 signaling complexes induced by vIL-6. J. Virol. 80: 9811-9821.
11. Adam N, Rabe B, Suthaus J, Grotzinger J, Rose-John S, Scheller J. 2009. Unraveling viral interleukin-6 binding to gp130 and activation of STATsignaling pathways independently of the interleukin-6 receptor. J. Virol. 83:5117-5126.
12. Boulanger MJ, Chow DC, Brevnova E, Martick M, Sandford G, Nicholas J, Garcia KC. 2004. Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. J. Mol. Biol. 335:641-654.
13. Hu F, Nicholas J. 2006. Signal transduction by human herpesvirus 8 viral interleukin-6 (vIL-6) is modulated by the nonsignaling gp80 subunit of the IL-6 receptor complex and is distinct from signaling induced by human IL-6. J. Virol. 80:10874-10878.
14. Meads MB, Medveczky PG. 2004. Kaposi's sarcoma-associated herpesvirus-encoded viral interleukin-6 is secreted and modified differently than human interleukin-6: evidence for a unique autocrine signaling mechanism. J. Biol. Chem. 279:51793-51803.
15. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334(Pt 2):297-314.
16. Kovaleva M, Bussmeyer I, Rabe B, Grotzinger J, Sudarman E, Eichler J, Conrad U, Rose-John S, Scheller J. 2006. Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J. Virol. 80:8510-8520.
17. Benekli M, Baumann H, Wetzler M. 2009. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol. 27:4422-4432.
18. Bowman T, Garcia R, Turkson J, Jove R. 2000. STATs in oncogenesis. Oncogene 19:2474-2488.
19. Hodge DR, Hurt EM, Farrar WL. 2005. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 41:2502-2512.
20. Aoki Y, Feldman GM, Tosato G. 2003. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101:1535-1542.
21. Oldenburg J, Bevans CG, Muller CR, Watzka M. 2006. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid. Redox Signal. 8:347-353.
22. Chen D, Cousins E, Sandford G, Nicholas J. 2012. Human herpesvirus 8 viral interleukin-6 interacts with splice variant 2 of vitamin K epoxide reductase complex subunit 1. J. Virol. 86:1577-1588.
23. Ho HH, Ivashkiv LB. 2006. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 281:14111-14118.
24. Huang F, Tong X, Fu L, Zhang R. 2008. Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo. Acta Biochim. Biophys. Sin. (Shanghai) 40:519-525.
25. Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC. 2004. Combined disruption of both the MEK/ERK and the IL-6R/ STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 104:3712-3721.
26. Wan X, Wang H, Nicholas J. 1999. Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. J. Virol. 73:8268-8278.
27. Chang LJ, Zaiss AK. 2003. Self-inactivating lentiviral vectors and a sensitive Cre-loxP reporter system. Methods Mol. Med. 76:367-382.
28. Nicholas J, Ruvolo VR, Burns WH, Sandford G, Wan X, Ciufo D, Hendrickson SB, Guo HG, Hayward GS, Reitz MS. 1997. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat. Med. 3:287-292.
29. Zhou BY, Ye Z, Chen G, Gao ZP, Zhang YA, Cheng L. 2007. Inducible and reversible transgene expression in human stem cells after efficient and stable gene transfer. Stem Cells 25:779-789.
30. Uddin S, Hussain AR, Manogaran PS, Al-Hussein K, Platanias LC, Gutierrez MI, Bhatia KG. 2005. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 24:7022-7030.
31. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. 2005. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106:1382-1391.
32. Cohen A, Brodie C, Sarid R. 2006. An essential role of ERK signalling in TPA-induced reactivation of Kaposi's sarcoma-associated herpesvirus. J. Gen. Virol. 87:795-802.
33. Ford PW, Bryan BA, Dyson OF, Weidner DA, Chintalgattu V, Akula SM. 2006. Raf/MEK/ERK signalling triggers reactivation of Kaposi's sarcoma-associated herpesvirus latency. J. Gen. Virol. 87:1139-1144.
34. Qin Z, DeFee M, Isaacs JS, Parsons C. 2010. Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV. Virology 403:92-102.
35. Xie J, Ajibade AO, Ye F, Kuhne K, Gao SJ. 2008. Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 371:139-154.
36. Pan H, Xie J, Ye F, Gao SJ. 2006. Modulation of Kaposi's sarcomaassociated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection. J. Virol. 80:5371-5382.
37. Sharma-Walia N, Krishnan HH, Naranatt PP, Zeng L, Smith MS, Chandran B. 2005. ERK1/2 and MEK1/2 induced by Kaposi's sarcomaassociated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J. Virol. 79:10308-10329.
38. Haura EB, Turkson J, Jove R. 2005. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract Oncol. 2:315-324.
39. Hirano T, Ishihara K, Hibi M. 2000. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19:2548-2556.
40. Punjabi AS, Carroll PA, Chen L, Lagunoff M. 2007. Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J. Virol. 81:2449-2458.
41. Morris VA, Punjabi AS, Lagunoff M. 2008. Activation of Akt through gp130 receptor signaling is required for Kaposi's sarcoma-associated herpesvirus-induced lymphatic reprogramming of endothelial cells. J. Virol. 82:8771-8779.